PL1989546T3 - Poszukiwanie związków o działaniu przeciwnowotworowym z zastosowaniem aktywności netryny-1 - Google Patents

Poszukiwanie związków o działaniu przeciwnowotworowym z zastosowaniem aktywności netryny-1

Info

Publication number
PL1989546T3
PL1989546T3 PL07726556T PL07726556T PL1989546T3 PL 1989546 T3 PL1989546 T3 PL 1989546T3 PL 07726556 T PL07726556 T PL 07726556T PL 07726556 T PL07726556 T PL 07726556T PL 1989546 T3 PL1989546 T3 PL 1989546T3
Authority
PL
Poland
Prior art keywords
netryna
searching
activity
compounds
cancer action
Prior art date
Application number
PL07726556T
Other languages
English (en)
Inventor
Patrick Mehlen
Agnès Bernet
Julien Fitamant
Original Assignee
Centre National De La Recherche Scientifique (Cnrs)
Centre Léon Bérard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique (Cnrs), Centre Léon Bérard filed Critical Centre National De La Recherche Scientifique (Cnrs)
Publication of PL1989546T3 publication Critical patent/PL1989546T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07726556T 2006-02-28 2007-02-28 Poszukiwanie związków o działaniu przeciwnowotworowym z zastosowaniem aktywności netryny-1 PL1989546T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77692606P 2006-02-28 2006-02-28

Publications (1)

Publication Number Publication Date
PL1989546T3 true PL1989546T3 (pl) 2017-03-31

Family

ID=38051332

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07726556T PL1989546T3 (pl) 2006-02-28 2007-02-28 Poszukiwanie związków o działaniu przeciwnowotworowym z zastosowaniem aktywności netryny-1

Country Status (21)

Country Link
US (3) US20090226458A1 (pl)
EP (1) EP1989546B1 (pl)
JP (1) JP5602368B2 (pl)
KR (2) KR20080113368A (pl)
CN (1) CN101389958B (pl)
AU (1) AU2007220515B2 (pl)
BR (1) BRPI0707040B8 (pl)
CA (1) CA2638974C (pl)
CY (1) CY1118325T1 (pl)
DK (1) DK1989546T3 (pl)
ES (1) ES2601352T3 (pl)
HU (1) HUE030738T2 (pl)
IL (1) IL193580A (pl)
LT (1) LT1989546T (pl)
MX (1) MX336675B (pl)
PL (1) PL1989546T3 (pl)
PT (1) PT1989546T (pl)
SG (1) SG172645A1 (pl)
SI (1) SI1989546T1 (pl)
WO (1) WO2007099133A1 (pl)
ZA (1) ZA200806913B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009141440A1 (en) * 2008-05-21 2009-11-26 Centre National De La Recherche Scientifique (Cnrs) Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma
EP2294416A1 (en) * 2008-05-21 2011-03-16 Centre National de la Recherche Scientifique - CNRS Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma
EP2208738A1 (en) 2009-01-09 2010-07-21 Centre National pour la Recherche Scientifique (CNRS) Method for the selection of endothelial cells death inducers via netrin-1 and its applications
US8052960B2 (en) * 2009-01-20 2011-11-08 The Penn State Research Foundation Netrin-1 as a biomarker of injury and disease
EP2267153A1 (en) * 2009-05-26 2010-12-29 Université Claude Bernard Lyon 1 Identification of netrin-1 receptor unc5c gene mutation in solid cancers
WO2011150299A2 (en) * 2010-05-28 2011-12-01 The Regents Of The University Of California Treatment of myocardial infarction and vascular injury with netrin-1
JP2013538051A (ja) * 2010-08-26 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Dccの第5フィブロネクチンタイプiiiドメインの組換えfc融合タンパク質
AU2012332481B2 (en) * 2011-11-04 2017-01-19 Invivis Sas Assay for predictive biomarkers of anti-estrogen efficacy
EP2708241A1 (en) 2012-09-12 2014-03-19 Netris Pharma Recombinant Fc-fusion protein of the two Immunoglobulin domains of UNC5
EP2708231A1 (en) 2012-09-12 2014-03-19 Netris Pharma Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
EP2893939A1 (en) * 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
CN105031611B (zh) * 2015-06-18 2018-02-09 中国医学科学院基础医学研究所 netrin‑1蛋白在制备用于肿瘤治疗的药物中的用途
AR106543A1 (es) 2015-11-02 2018-01-24 Netris Pharma Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
US10379534B2 (en) * 2016-01-28 2019-08-13 Qualcomm Incorporated Drone flight control
CN107011444B (zh) * 2016-01-28 2021-11-16 中国科学院脑科学与智能技术卓越创新中心 一种筛选hERG钾离子通道激动剂和毒性检测方法
CN105925578A (zh) * 2016-05-30 2016-09-07 东北师范大学 靶向沉默Neogenin的shRNA
US12162932B2 (en) 2017-01-05 2024-12-10 Netris Pharma Combined treatment with Netrin-1 interfering drug and immune checkpoint inhibitors drugs
US20230204565A1 (en) * 2020-01-02 2023-06-29 The Regents Of The University Of California Methods for Culturing Cancer Cells and for Inhibiting Invasion of Cancer
CN112812167B (zh) * 2021-01-06 2023-04-11 东北师范大学 一种促进细胞存活的Netrin-1模拟肽、Netrin-1截短多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5565331A (en) 1993-11-12 1996-10-15 The Regents Of The University Of California Nucleic acids encoding neural axon outgrowth modulators
US6030806A (en) 1995-06-30 2000-02-29 Landes; Gregory M. Human chromosome 16 genes, compositions, methods of making and using same
JPH11509408A (ja) 1995-06-30 1999-08-24 ジェンザイム コーポレイション 新規なヒト第16染色体遺伝子、組成物、それらの製造および使用方法
US5824775A (en) 1996-04-19 1998-10-20 The Regents Of The University Of California Human netrin-1
JPH11335398A (ja) 1998-05-22 1999-12-07 Hoechst Marion Roussel Kk 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬
US5939271A (en) 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
US20060025335A1 (en) * 2004-01-30 2006-02-02 Kinane Thomas B Netrin compositions and methods of using the same
EP1751188A1 (en) * 2004-06-04 2007-02-14 Applied Research Systems ARS Holding N.V. Splice variant of unc5h2
WO2006019904A1 (en) * 2004-07-14 2006-02-23 University Of Utha Research Foundation Netrin-related compositions and uses
WO2006054000A2 (fr) 2004-11-22 2006-05-26 Centre National De La Recherche Scientifique Netrine 4 mutee, ses fragments et leur utilisation comme medicaments
US20060153840A1 (en) * 2005-01-12 2006-07-13 Anne Eichmann Methods for preventing or treating a condition or a disease associated with angiogenesis
CA2489780A1 (en) 2005-01-12 2006-07-12 Inserm Methods for preventing or treating a condition or a disease associated with angiogenesis
JP4677376B2 (ja) 2006-07-07 2011-04-27 キヤノン株式会社 画像処理装置、画像処理方法、画像処理プログラム及び記憶媒体
WO2009141440A1 (en) * 2008-05-21 2009-11-26 Centre National De La Recherche Scientifique (Cnrs) Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma

Also Published As

Publication number Publication date
CA2638974C (en) 2018-07-24
EP1989546B1 (en) 2016-08-31
JP2009528525A (ja) 2009-08-06
CN101389958B (zh) 2014-04-09
BRPI0707040A2 (pt) 2011-04-12
US20090226458A1 (en) 2009-09-10
KR20080113368A (ko) 2008-12-30
ZA200806913B (en) 2009-08-26
WO2007099133A1 (en) 2007-09-07
AU2007220515A1 (en) 2007-09-07
AU2007220515B2 (en) 2013-02-14
LT1989546T (lt) 2016-12-27
EP1989546A1 (en) 2008-11-12
BRPI0707040B1 (pt) 2021-11-23
US20180291106A1 (en) 2018-10-11
PT1989546T (pt) 2016-12-05
KR20140129391A (ko) 2014-11-06
US20150004159A1 (en) 2015-01-01
DK1989546T3 (en) 2016-11-21
CA2638974A1 (en) 2007-09-07
SG172645A1 (en) 2011-07-28
IL193580A (en) 2013-08-29
CN101389958A (zh) 2009-03-18
MX336675B (es) 2016-01-27
SI1989546T1 (sl) 2016-12-30
IL193580A0 (en) 2009-02-11
BRPI0707040B8 (pt) 2022-03-08
ES2601352T3 (es) 2017-02-14
JP5602368B2 (ja) 2014-10-08
US11203641B2 (en) 2021-12-21
CY1118325T1 (el) 2017-06-28
HUE030738T2 (en) 2017-05-29
KR101587932B1 (ko) 2016-01-22
MX2008011067A (es) 2008-11-25

Similar Documents

Publication Publication Date Title
PL1989546T3 (pl) Poszukiwanie związków o działaniu przeciwnowotworowym z zastosowaniem aktywności netryny-1
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
BRPI0718874A2 (pt) Compostos orgânicos
NO20084803L (no) organiske forbindelser
BRPI0718478A2 (pt) Compostos orgânicos
ATE524477T1 (de) Aziridinylepothilonverbindungen
DK2041139T3 (da) Farmaceutiske forbindelser
BRPI0714512A2 (pt) Compostos químicos
BRPI0718509A2 (pt) compostos orgânicos heterocíclicos
DK2089364T3 (da) Pyridinonforbindelser
BRPI0813500A2 (pt) Compostos antivirais
NO347644B1 (no) Polymorfer
BRPI0821086A2 (pt) Compostos inseticidas
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
BRPI0817434A2 (pt) Composto orgânicos
BRPI0712902A2 (pt) compostos orgânicos
ATE463498T1 (de) Imidazo-verbindungen
BRPI0811562A2 (pt) Compostos orgânicos
BRPI0811264A2 (pt) Compostos
BRPI0809996A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0818005A2 (pt) Compostos orgânicos
EP2208972A4 (en) COMBINATION SCALE
DE602007013849D1 (de) Mikroreaktor
BRPI0813739A2 (pt) compostos orgânicos